PHARMASTAT CONSULTING LTDActive

Company number 08793953Private limited companyIncorporated 2013

Key figures

£58,145-1.3%
Net assets 2024/25
-9.6%
Average annual change 2019/20–2024/25
025 k50 k75 k100 k2019/202020/212021/222022/232023/242024/25

Like most small UK companies, PHARMASTAT CONSULTING LTD does not publish a profit and loss account in its latest accounts. The figures below come from the balance sheet.

Ratios

2024/25
Balance sheet structure
Current assetsFixed assetsLiabilitiesNet assets
050 k100 k150 k2019/202020/212021/222022/232023/242024/25
Filed accounts2019/20–2024/25
2020/212021/222022/232023/242024/25
Cash at bank and in hand114,159128,315112,11186,20584,706
Total assets140,822143,835137,765100,74084,724
Total liabilities45,26145,36647,52241,83826,579
Net assets / total equity95,56198,46990,24358,90258,145
Average number of employees11111

A dash (—) means no accounts were filed for that year or the item is not in the accounts; 0 is a zero stated in the accounts. Small companies usually file only a balance sheet, so the profit and loss account is often missing.

Summary: PHARMASTAT CONSULTING LTD

Company

PHARMASTAT CONSULTING LTD is a private limited company registered with Companies House under company number 08793953. It was incorporated on 28 Nov 2013. Its status is active. The registered office is in Canterbury (CT4). Its nature of business (SIC 2007) is other professional, scientific and technical activities n.e.c. (74909).

Accounts

The latest accounts in the database are for 2024/25 (period ending 30 Nov 2025); the company files small company accounts (filleted). Net assets were £58,145, down 1.3% on the previous year. Cash at bank and in hand was £84,706. Total assets were £84,724 and total liabilities £26,579. The company had an average of 1 employee. Figures are available for 6 financial years (2019/20–2024/25).

Control and charges

One person with significant control is registered.

Filing deadlines

The next accounts are due by 31 Aug 2027. The next confirmation statement is due by 12 Dec 2026.